Does Varicella zoster virus has potential for oncogenicity?
Reading File
Searching PubMed
Varicella zoster virus oncogenicity cancer
Searching the Web
Varicella zoster virus oncogenic potential cancer association evidence 2024
Finding Sources
Finding Sources
Searching PubMed
varicella zoster virus glioma cancer association
Reading File
Reading Article
Reading Article
Reading File
Reading Web Page
VZV oncogenicity cancer mechanism
I now have comprehensive information from textbooks and recent literature to give a thorough answer. Here is the full synthesis:
Does Varicella Zoster Virus (VZV) Have Potential for Oncogenicity?
The short answer is: yes, VZV carries a recognized potential for oncogenicity, but it is listed among viruses with that potential rather than being a proven, independent cancer-causing virus in humans. The modern research picture is actually more complex - VZV appears to be more of a possible anti-tumor agent than a driver of malignancy.
What Textbooks Say
Park's Textbook of Preventive and Social Medicine explicitly states, among VZV complications:
"The virus has a potential for oncogenicity."
- Park's Textbook of Preventive and Social Medicine, p. (block2, line 5462-5463)
Roitt's Essential Immunology lists VZV within the broader herpesvirus family (along with HSV, CMV, EBV, and Marek's disease virus) under the group of viruses that include "oncogenic" members - i.e., budding viruses with potential to cause cellular transformation:
"...herpes (simplex, varicella zoster, cytomegalo, Epstein-Barr, Marek's disease)..." - grouped with oncogenic RNA and DNA viruses in Figure 11.21.
- Roitt's Essential Immunology, p. 363
Biological Basis for Oncogenic Potential
VZV is classified as an alpha-herpesvirus (Human Herpesvirus 3). Several features of herpesviruses in general confer oncogenic risk:
- Genomic integration and latency - VZV establishes latency in dorsal root ganglia; like other herpesviruses, reactivation can induce genomic instability.
- Immunosuppression and immune evasion - VZV encodes functions that interfere with IFN-gamma signal transduction via the JAK/STAT pathway, inhibiting MHC class II upregulation. This blunting of immune surveillance creates a permissive environment for tumor escape.
- Chronic reactivation effects - Herpes zoster (VZV reactivation) has been epidemiologically associated with some cancers, possibly because both share a common substrate of weakened cell-mediated immunity.
- Inflammatory mechanisms - VZV induces NLRP3 inflammasome formation and promotes IL-1beta processing via activated caspase-1, contributing to a pro-inflammatory microenvironment.
The Glioma-VZV Relationship: An Inverse (Protective) Association
This is the most studied cancer-VZV link, and the findings are counterintuitive:
-
A 2023 Mendelian randomization study (Zhong et al., BMC Medicine, PMID: 38053181) using GWAS data from 12,488 glioma cases found that genetically predicted herpes zoster significantly decreased risk of low-grade glioma (OR = 0.85, 95% CI: 0.76-0.96, FDR = 0.04). This is some of the strongest causal evidence to date.
-
A 2023 Neuro-Oncology study (Guerra et al., PMID: 36610073) analyzed 1,378 adult glioma patients and found that VZV antibody seropositivity was associated with improved survival (HR = 0.70, p = 0.006). Higher VZV antibody levels correlated with better outcomes.
-
VZV has demonstrated intrinsic oncolytic potential in malignant glioma cell cultures and has been proposed as a candidate for virotherapy in glioblastoma multiforme (GBM). A VZV strain engineered with ORF8 deletion and armed with IL-12 has been evaluated as an oncolytic agent (Jiang et al., J Immunother Cancer, 2024).
Head and Neck Cancers
A 2024 Scientific Reports study (Chen et al.) found associations between herpes zoster and head and neck cancers (HNC) diagnosed within 5 years of HZ. The proposed mechanisms include:
- Both conditions share diminished cell-mediated immunity as a common predisposing factor
- VZV reactivation may trigger immunologic mechanisms that weaken cancer immune surveillance
- The relationship is likely bidirectional - pre-clinical cancer may impair immunity enough to trigger VZV reactivation, rather than VZV causing the cancer directly
How VZV Compares to Definitively Oncogenic Herpesviruses
| Virus | Oncogenic Status | Associated Cancer |
|---|---|---|
| EBV (HHV-4) | Proven oncovirus | Burkitt's lymphoma, NPC, EBV+ DLBCL |
| KSHV (HHV-8) | Proven oncovirus | Kaposi's sarcoma, PEL |
| CMV (HHV-5) | Debated/possible | Possible glioblastoma promotion |
| VZV (HHV-3) | Potential, not proven | No definitive cancer; inverse glioma association |
Summary
VZV has an acknowledged potential for oncogenicity - it encodes immune evasion mechanisms, shares the herpesvirus family property of possible genomic integration, and clinical data show associations between herpes zoster and some cancers (likely through shared immunosuppression). However, the current evidence strongly suggests that VZV exposure and immune response to it is more likely protective against glioma than causative. Its actual clinical interest in oncology is shifting toward oncolytic virotherapy as a treatment rather than a cause of cancer. The statement in Park's textbook reflects the broader herpesvirus class property, not a proven direct carcinogenic mechanism specific to VZV.
Key references:
- Park's Textbook of Preventive and Social Medicine (direct oncogenicity statement)
- Zhong S et al. VZV and glioma risk MR analysis, BMC Med 2023 [PMID: 38053181]
- Guerra G et al. VZV antibodies and glioma survival, Neuro Oncol 2023 [PMID: 36610073]
- Roitt's Essential Immunology, Fig. 11.21 classification
This is a shared conversation. Sign in to Orris to start your own chat.